REFERENCES
- Pauwels R A, Rabe K F. Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet 2004; 364(9434)613–620, [PUBMED], [INFOTRIEVE], [CSA]
- Pauwels R A, Buist A S, Calverley P M, Jenkins C R, Hurd S S. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001; 163(5)1256–1276, [PUBMED], [INFOTRIEVE], [CSA]
- Pesci A, Balbi B, Majori M, Cacciani G, Bertacco S, Alciato P, Donner C F. Inflammatory cells and mediators in bronchial lavage of patients with chronic obstructive pulmonary disease. Eur Respir J 1998; 12(2) 380–386, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Saetta M, Baraldo S, Corbino L, Turato G, Braccioni F, Rea F, Cavallesco G, Tropeano G, Mapp C E, Maestrelli P, Ciaccia A, Fabbri L M. CD8+ve cells in the lungs of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160(2)711–717, [PUBMED], [INFOTRIEVE], [CSA]
- Vernooy J H, Kucukaycan M, Jacobs J A, Chavannes N H, Buurman W A, Dentener M A, Wouters E F. Local and systemic inflammation in patients with chronic obstructive pulmonary disease: soluble tumor necrosis factor receptors are increased in sputum. Am J Respir Crit Care Med 2002; 166(9)1218–1224, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Hogg J C, Chu F, Utokaparch S, Woods R, Elliott W M, Buzatu L, Cherniack R M, Rogers R M, Sciurba F C, Coxson H O, Pare P D. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004; 350(26)2645–2653, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- O'Shaughnessy T C, Ansari T W, Barnes N C, Jeffery P K. Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD8+ T lymphocytes with FEV1. Am J Respir Crit Care Med 1997; 155(3)852–857, [PUBMED], [INFOTRIEVE], [CSA]
- Stanescu D, Sanna A, Veriter C, Kostianev S, Calcagni P G, Fabbri L M, Maestrelli P. Airways obstruction, chronic expectoration, and rapid decline of FEV1 in smokers are associated with increased levels of sputum neutrophils. Thorax 1996; 51(3)267–271, [PUBMED], [INFOTRIEVE], [CSA]
- Beeh K M, Kornmann O, Buhl R, Culpitt S V, Giembycz M A, Barnes P J. Neutrophil chemotactic activity of sputum from patients with COPD: role of interleukin 8 and leukotriene B4. Chest 2003; 123(4)1240–1247, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Oudijk E J, Lammers J W, Koenderman L. Systemic inflammation in chronic obstructive pulmonary disease. Eur Respir J Suppl 2003; 46: 5s–13s, [PUBMED], [INFOTRIEVE], [CSA]
- Wouters E F. Local and systemic inflammation in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005; 2: 26–33, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Di Francia M, Barbier D, Mege J L, Orehek J. Tumor necrosis factor-alpha levels and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1994; 150(5 Pt 1)1453–1455, [PUBMED], [INFOTRIEVE], [CSA]
- Schols A M, Buurman W A, Staal van den Brekel A J, Dentener M A, Wouters E F. Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. Thorax 1996; 51(8)819–824, [PUBMED], [INFOTRIEVE], [CSA]
- Schols A M, Creutzberg E C, Buurman W A, Campfield L A, Saris W H, Wouters E F. Plasma leptin is related to proinflammatory status and dietary intake in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160(4)1220–1226, [PUBMED], [INFOTRIEVE], [CSA]
- Dentener M A, Creutzberg E C, Schols A M, Mantovani A, van't Veer C, Buurman W A, Wouters E F. Systemic anti-inflammatory mediators in COPD: increase in soluble interleukin 1 receptor II during treatment of exacerbations. Thorax 2001; 56(9)721–726, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Takabatake N, Nakamura H, Inoue S, Terashita K, Yuki H, Kato S, Yasumura S, Tomoike H. Circulating levels of soluble Fas ligand and soluble Fas in patients with chronic obstructive pulmonary disease. Respir Med 2000; 94(12)1215–1220, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Noguera A, Batle S, Miralles C, Iglesias J, Busquets X, MacNee W, Agusti A G. Enhanced neutrophil response in chronic obstructive pulmonary disease. Thorax 2001; 56(6)432–437, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Gan W Q, Man S F, Senthilselvan A, Sin D D. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004; 59(7)574–580, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- de Godoy I, Donahoe M, Calhoun W J, Mancino J, Rogers R M. Elevated TNF-alpha production by peripheral blood monocytes of weight-losing COPD patients. Am J Respir Crit Care Med 1996; 153(2)633–637, [PUBMED], [INFOTRIEVE], [CSA]
- Jagoe R T, Engelen M P. Muscle wasting and changes in muscle protein metabolism in chronic obstructive pulmonary disease. Eur Respir J Suppl 2003; 46: 52s–63s, [PUBMED], [INFOTRIEVE], [CSA]
- Wouters E F, Creutzberg E C, Schols A M. Systemic effects in COPD. Chest 2002; 121(5 Suppl)127S–130S, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Broekhuizen R, Wouters E F, Creutzberg E C, Schols A M. Raised CRP levels mark metabolic and functional impairment in advanced COPD. Thorax 2006; 61(1)17–22, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Sin D D, Man S F. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003; 107(11)1514–1519, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Barnes P J. Chronic obstructive pulmonary disease. N Engl J Med 2000; 343(4)269–280, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Sato E, Koyama S S, Takamizawa S, Masubuchi T, Kubo K, Robbins R A, Nagai S, Izumi T. Smoke extract stimulates lung fibroblasts to release neutrophil and monocyte chemotactic activities. Am J Physiol 1999; 277(6 Pt 1)L1149–L1157, [PUBMED], [INFOTRIEVE], [CSA]
- Shapiro S D. The macrophage in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160(5 Pt 2)S29–S32, [PUBMED], [INFOTRIEVE], [CSA]
- Hoshino S, Yoshida M, Inoue K, Yano Y, Yanagita M, Mawatari H, Yamane H, Kijima T, Kumagai T, Osaki T, Tachiba I, Kawase I. Cigarette smoke extract induces endothelial cell injury via JNK pathway. Biochem Biophys Res Commun 2005; 329(1)58–63, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Rennard S I. Inflammation and repair processes in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160(5 Pt 2)S12–S16, [PUBMED], [INFOTRIEVE], [CSA]
- Keatings V M, Collins P D, Scott D M, Barnes P J. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 1996; 153(2)530–534, [PUBMED], [INFOTRIEVE], [CSA]
- Turato G, Di Stefano A, Maestrelli P, Mapp C E, Ruggieri M P, Roggeri A, Fabbri L M, Saetta M. Effect of smoking cessation on airway inflammation in chronic bronchitis. Am J Respir Crit Care Med 1995; 152(4 Pt 1)1262–1267, [PUBMED], [INFOTRIEVE], [CSA]
- Bergmann S, Siekmeier R, Mix C, Jaross W. Even moderate cigarette smoking influences the pattern of circulating monocytes and the concentration of sICAM-1. Respir Physiol 1998; 114(3)269–275, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Rutgers S R, Timens W, Kaufmann H F, van der Mark T W, Koeter G H, Postma D S. Comparison of induced sputum with bronchial wash, bronchoalveolar lavage and bronchial biopsies in COPD. Eur Respir J 2000; 15(1)109–115, [PUBMED], [INFOTRIEVE], [CSA]
- van Eeden S F, Tan W C, Suwa T, Mukae H, Terashima T, Fujii T, Qui D, Vincent R, Hogg J C. Cytokines involved in the systemic inflammatory response induced by exposure to particulate matter air pollutants (PM(10)). Am J Respir Crit Care Med 2001; 164(5)826–830, [PUBMED], [INFOTRIEVE], [CSA]
- Tan W C, Qiu D, Liam B L, Ng T P, Lee S H, van Eeden S F, D'Yachkova Y, Hogg J C. The human bone marrow response to acute air pollution caused by forest fires. Am J Respir Crit Care Med 2000; 161(4 Pt 1)1213–1217, [PUBMED], [INFOTRIEVE], [CSA]
- Koenderman L, Kanters D, Maesen B, Raaijmakers J, Lammers J W, de Kruif J, Logtenberg T. Monitoring of neutrophil priming in whole blood by antibodies isolated from a synthetic phage antibody library. J Leukoc Biol 2000; 68(1)58–64, [PUBMED], [INFOTRIEVE], [CSA]
- Oudijk E J, Nijhuis E H, Zwank M D, van de Graaf E A, Mager H J, Coffer P J, Lammers J W, Koenderman L. Systemic inflammation in COPD visualised by gene profiling in peripheral blood neutrophils. Thorax 2005; 60(7)538–544, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Gan W Q, Man S F, Sin D D. The interactions between cigarette smoking and reduced lung function on systemic inflammation. Chest 2005; 127(2)558–564, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- van der Vaart H, Koeter G H, Postma D S, Kauffman H F, Ten Hacken N H. First study of infliximab treatment in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 172(4)465–469, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Pisetsky D S. Tumor necrosis factor blockers in rheumatoid arthritis. N Engl J Med 2000; 342(11)810–811, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Kopp S, Alstergren P, Ernestam S, Nordahl S, Morin P, Bratt J. Reduction of temporomandibular joint pain after treatment with a combination of methotrexate and infliximab is associated with changes in synovial fluid and plasma cytokines in rheumatoid arthritis. Cells Tissues Organs 2005; 180(1)22–30, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Takabatake N, Nakamura H, Abe S, Inoue S, Hino T, Saito H, Yuki H, Kato S, Tomoike H. The relationship between chronic hypoxemia and activation of the tumor necrosis factor-alpha system in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161(4 Pt 1)1179–1184, [PUBMED], [INFOTRIEVE], [CSA]
- Yu A Y, Frid M G, Shimoda L A, Wiener C M, Stenmark K, Semenza G L. Temporal, spatial, and oxygen-regulated expression of hypoxia-inducible factor-1 in the lung. Am J Physiol 1998; 275(4 Pt 1)L818–L826, [PUBMED], [INFOTRIEVE], [CSA]
- Agusti A, MacNee W, Donaldson K, Cosio M. Hypothesis: does COPD have an autoimmune component?. Thorax 2003; 58(10)832–834, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Delves P J, Roitt I M. The immune system. First of two parts. N Engl J Med 2000; 343(1)37–49, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Koethe S M, Kuhnmuench J R, Becker C G. Neutrophil priming by cigarette smoke condensate and a tobacco anti-idiotypic antibody. Am J Pathol 2000; 157(5)1735–1743, [PUBMED], [INFOTRIEVE], [CSA]
- Becker C G, Dubin T, Wiedemann H P. Hypersensitivity to tobacco antigen. Proc Natl Acad Sci USA 1976; 73(5)1712–1716, [PUBMED], [INFOTRIEVE], [CSA]
- Francus T, Romano P M, Manzo G, Fonacier L, Arango N, Szabo P. IL-1, IL-6, and PDGF mRNA expression in alveolar cells following stimulation with a tobacco-derived antigen. Cell Immunol 1992; 145(1)156–174, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Waterer G W, Wunderink R G. Science review: Genetic variability in the systemic inflammatory response. Crit Care 2003; 7(4)308–314, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- De Maio A, Torres M B, Reeves R H. Genetic determinants influencing the response to injury, inflammation, and sepsis. Shock 2005; 23(1)11–17, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Brueckmann M, Bertsch T, Lang S, Sueselbeck T, Wolpert C, Kaden J J, Jaramillo C, Huhle G, Borggrefe M, Haase K K. Time course of systemic markers of inflammation in patients presenting with acute coronary syndromes. Clin Chem Lab Med 2004; 42(10)1132–1139, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Ridker P M, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000; 101(18)2149–2153, [PUBMED], [INFOTRIEVE], [CSA]
- Beck G J, Doyle C A, Schachter E N. Smoking and lung function. Am Rev Respir Dis 1981; 123(2)149–155, [PUBMED], [INFOTRIEVE], [CSA]
- Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J 1977; 1(6077)1645–1648, [PUBMED], [INFOTRIEVE], [CSA]
- Joos L, Pare P D, Sandford A J. Genetic risk factors of chronic obstructive pulmonary disease. Swiss Med Wkly 2002; 132(3–4)27–37, [PUBMED], [INFOTRIEVE], [CSA]
- Knight J C. Regulatory polymorphisms underlying complex disease traits. J Mol Med 2005; 83(2)97–109, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Collins F S, Guyer M S, Charkravarti A. Variations on a theme: cataloging human DNA sequence variation. Science 1997; 278(5343)1580–1581, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Taylor J G, Choi E H, Foster C B, Chanock S J. Using genetic variation to study human disease. Trends Mol Med 2001; 7(11)507–512, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Dev D, Wallace E, Sankaran R, Cunniffe J, Govan J R, Wathen C G, Emmanuel F X. Value of C-reactive protein measurements in exacerbations of chronic obstructive pulmonary disease. Respir Med 1998; 92(4)664–667, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Cano N J, Pichard C, Roth H, Court-Fortune I, Cynober L, Gerard-Boncompain M, Cuvelier A, Laaban J P, Melchior J C, Raphael J C, Pison C M. C-reactive protein and body mass index predict outcome in end-stage respiratory failure. Chest 2004; 126(2)540–546, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Creutzberg E, Postma S, Hop J, Vermue A, Derks J, Wouters E. Systemic inflammatory response during one year follow-up in patients with COPD. Eur Respir J 2004; 24(Suppl. 48)13s, [CSA]
- Hansell A L, Walk J A, Soriano J B. What do chronic obstructive pulmonary disease patients die from? A multiple cause coding analysis. Eur Respir J 2003; 22(5)809–814, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Szmitko P E, Wang C H, Weisel R D, de Almeida J R, Anderson T J, Verma S. New markers of inflammation and endothelial cell activation: Part I. Circulation 2003; 108(16)1917–1923, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Verma S, Li S H, Badiwala M V, Weisel R D, Fedak P W, Li R K, Dhillon B, Mickle D A. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 2002; 105(16)1890–1896, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Paul A, Ko K W, Li L, Yechoor V, McCrory M A, Szalai A J, Chan L. C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Circulation 2004; 109(5)647–655, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Jialal I, Devaraj S, Venugopal S K. C-reactive protein: risk marker or mediator in atherothrombosis?. Hypertension 2004; 44(1)6–11, [PUBMED], [CROSSREF], [CSA]
- Manolov D E, Koenig W, Hombach V, Torzewski J. C-reactive protein and atherosclerosis. Is there a causal link? Histol Histopathol 2003; 18(4)1189–1193, [CSA]
- Pankow J S, Folsom A R, Cushman M, Borecki I B, Hopkins P N, Eckfeldt J H, Tracy R P. Familial and genetic determinants of systemic markers of inflammation: the NHLBI family heart study. Atherosclerosis 2001; 154(3)681–689, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Retterstol L, Eikvar L, Berg K. A twin study of C-reactive protein compared to other risk factors for coronary heart disease. Atherosclerosis 2003; 169(2)279–282, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Russell A I, Cunninghame Graham D S, Shepherd C, Roberton C A, Whittaker J, Meeks J, Powell R J, Isenberg D A, Walport M J, Vyse T J. Polymorphism at the C-reactive protein locus influences gene expression and predisposes to systemic lupus erythematosus. Hum Mol Genet 2004; 13(1)137–147, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Zee R Y, Ridker P M. Polymorphism in the human C-reactive protein (CRP) gene, plasma concentrations of CRP, and the risk of future arterial thrombosis. Atherosclerosis 2002; 162(1)217–219, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Szalai A J, McCrory M A, Cooper G S, Wu J, Kimberly R P. Association between baseline levels of C-reactive protein (CRP) and a dinucleotide repeat polymorphism in the intron of the CRP gene. Genes Immun 2002; 3(1)14–19, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Brull D J, Serrano N, Zito F, Jones L, Montgomery H E, Rumley A, Sharma P, Lowe G D, World M J, Humphries S E, Hingorani A D. Human CRP gene polymorphism influences CRP levels: implications for the prediction and pathogenesis of coronary heart disease. Arterioscler Thromb Vasc Biol 2003; 23(11)2063–2069, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Szalai A J, Wu J, Lange E M, McCrory M A, Langefeld C D, Williams A, Zakharkin S O, George V, Allison D B, Cooper G S, Xie F, Fan Z, Edberg J C, Kimberly R P. Single-nucleotide polymorphisms in the C-reactive protein (CRP) gene promoter that affect transcription factor binding, alter transcriptional activity, and associate with differences in baseline serum CRP level. J Mol Med 2005; 83(6)440–447, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Gaur U, Aggarwal B B. Regulation of proliferation, survival and apoptosis by members of the TNF superfamily. Biochem Pharmacol 2003; 66(8)1403–1408, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- McDevitt H, Munson S, Ettinger R, Wu A. Multiple roles for tumor necrosis factor-alpha and lymphotoxin alpha/beta in immunity and autoimmunity. Arthritis Res 2002; 4(Suppl 3)S141–S152, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Wallach D, Varfolomeev E E, Malinin N L, Goltsev Y V, Kovalenko A V, Boldin M P. Tumor necrosis factor receptor and Fas signaling mechanisms. Annu Rev Immunol 1999; 17: 331–367, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Mueller R, Chanez P, Campbell A M, Bousquet J, Heusser C, Bullock G R. Different cytokine patterns in bronchial biopsies in asthma and chronic bronchitis. Respir Med 1996; 90(2)79–85, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Sun G, Stacey M A, Vittori E, Marini M, Bellini A, Kleimberg J, Mattoli S. Cellular and molecular characteristics of inflammation in chronic bronchitis. Eur J Clin Invest 1998; 28(5)364–372, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Eid A A, Ionescu A A, Nixon L S, Lewis-Jenkins V, Matthews S B, Griffiths T L, Shale D J. Inflammatory response and body composition in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164(8 Pt 1)1414–1418, [PUBMED], [INFOTRIEVE], [CSA]
- Hageman G J, Larik I, Pennings H J, Haenen G R, Wouters E F, Bast A. Systemic poly(ADP-ribose) polymerase-1 activation, chronic inflammation, and oxidative stress in COPD patients. Free Radic Biol Med 2003; 35(2)140–148, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Yasuda N, Gotoh K, Minatoguchi S, Asano K, Nishigaki K, Nomura M, Ohno A, Watanabe M, Sano H, Kumada H, Sawa T, Fujiwara H. An increase of soluble Fas, an inhibitor of apoptosis, associated with progression of COPD. Respir Med 1998; 92(8)993–999, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Hajeer A H, Hutchinson I V. Influence of TNFalpha gene polymorphisms on TNFalpha production and disease. Hum Immunol 2001; 62(11)1191–1199, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Bouma G, Crusius J B, Oudkerk Pool M, Kolkman J J, von Blomberg B M, Kostense P J, Giphart M J, Schreuder G M, Meuwissen S G, Pena A S. Secretion of tumour necrosis factor alpha and lymphotoxin alpha in relation to polymorphisms in the TNF genes and HLA-DR alleles. Relevance for inflammatory bowel disease. Scand J Immunol 1996; 43(4)456–463, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Wilson A G, Symons J A, McDowell T L, McDevitt H O, Duff G W. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA 1997; 94(7)3195–3199, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Mycko M, Kowalski W, Kwinkowski M, Buenafe A C, Szymanska B, Tronczynska E, Plucienniczak A, Selmaj K. Multiple sclerosis: the frequency of allelic forms of tumor necrosis factor and lymphotoxin-alpha. J Neuroimmunol 1998; 84(2)198–206, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Pociot F, Briant L, Jongeneel C V, Molvig J, Worsaae H, Abbal M, Thomsen M, Nerup J, Cambon-Thomsen A. Association of tumor necrosis factor (TNF) and class II major histocompatibility complex alleles with the secretion of TNF-alpha and TNF-beta by human mononuclear cells: a possible link to insulin-dependent diabetes mellitus. Eur J Immunol 1993; 23(1)224–231, [PUBMED], [INFOTRIEVE], [CSA]
- Uglialoro A M, Turbay D, Pesavento P A, Delgado J C, McKenzie F E, Gribben J G, Hartl D, Yunis E J, Goldfeld A E. Identification of three new single nucleotide polymorphisms in the human tumor necrosis factor-alpha gene promoter. Tissue Antigens 1998; 52(4)359–367, [PUBMED], [INFOTRIEVE], [CSA]
- Huizinga T W, Westendorp R G, Bollen E L, Keijsers V, Brinkman B M, Langermans J A, Breedveld F C, Verweij C L, van de Gaer L, Dams L, Crusius J B, Garcia-Gonzalez A, van Oosten B W, Polman C H, Pena A S. TNF-alpha promoter polymorphisms, production and susceptibility to multiple sclerosis in different groups of patients. J Neuroimmunol 1997; 72(2)149–153, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Mira J P, Cariou A, Grall F, Delclaux C, Losser M R, Heshmati F, Cheval C, Monchi M, Teboul J L, Riche F, Leleu G, Arbibe L, Mignon A, Delpech M, Dhainaut J F. Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: a multicenter study. JAMA 1999; 282(6)561–568, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- McGuire W, Hill A V, Allsopp C E, Greenwood B M, Kwiatkowski D. Variation in the TNF-alpha promoter region associated with susceptibility to cerebral malaria. Nature 1994; 371(6497)508–510, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Brinkman B M, Huizinga T W, Breedveld F C, Verweij C L. Allele-specific quantification of TNFA transcripts in rheumatoid arthritis. Hum Genet 1996; 97(6)813–818, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Chagani T, Pare P D, Zhu S, Weir T D, Bai T R, Behbehani N A, Fitzgerald J M, Sandford A J. Prevalence of tumor necrosis factor-alpha and angiotensin converting enzyme polymorphisms in mild/moderate and fatal/near-fatal asthma. Am J Respir Crit Care Med 1999; 160(1)278–282, [PUBMED], [INFOTRIEVE], [CSA]
- Albuquerque R V, Hayden C M, Palmer L J, Laing I A, Rye P J, Gibson N A, Burton P R, Goldblatt J, Lesouef P N. Association of polymorphisms within the tumour necrosis factor (TNF) genes and childhood asthma. Clin Exp Allergy 1998; 28(5)578–584, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Sakao S, Tatsumi K, Igari H, Shino Y, Shirasawa H, Kuriyama T. Association of tumor necrosis factor alpha gene promoter polymorphism with the presence of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163(2)420–422, [PUBMED], [INFOTRIEVE], [CSA]
- Huang S L, Su C H, Chang S C. Tumor necrosis factor-alpha gene polymorphism in chronic bronchitis. Am J Respir Crit Care Med 1997; 156(5)1436–1439, [PUBMED], [INFOTRIEVE], [CSA]
- Ferrarotti I, Zorzetto M, Beccaria M, Gile L S, Porta R, Ambrosino N, Pignatti P F, Cerveri I, Pozzi E, Luisetti M. Tumour necrosis factor family genes in a phenotype of COPD associated with emphysema. Eur Respir J 2003; 21(3)444–449, [PUBMED], [INFOTRIEVE], [CSA]
- Sandford A J, Chagani T, Weir T D, Connett J E, Anthonisen N R, Pare P D. Susceptibility genes for rapid decline of lung function in the lung health study. Am J Respir Crit Care Med 2001; 163(2)469–473, [PUBMED], [INFOTRIEVE], [CSA]
- Kucukaycan M, Van Krugten M, Pennings H J, Huizinga T W, Buurman W A, Dentener M A, Wouters E F. Tumor Necrosis Factor-alpha +489G/A gene polymorphism is associated with chronic obstructive pulmonary disease. Respir Res 2002; 3(1)29, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Keatings V M, Cave S J, Henry M J, Morgan K, O'Connor C M, Fitz Gerald M X, Kalsheker N. A polymorphism in the tumor necrosis factor-alpha gene promoter region may predispose to a poor prognosis in COPD. Chest 2000; 118(4)971–975, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Hersh C P, Demeo D L, Lange C, Litonjua A A, Reilly J J, Kwiatkowski D, Laird N, Sylvia J S, Sparrow D, Speizer F E, Weiss S T, Silverman E K. Attempted Replication of Reported Chronic Obstructive Pulmonary Disease Candidate Gene Associations. Am J Respir Cell Mol Biol 2005; 33(1)71–78, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Grove J, Daly A K, Bassendine M F, Day C P. Association of a tumor necrosis factor promoter polymorphism with susceptibility to alcoholic steatohepatitis. Hepatology 1997; 26(1)143–146, [PUBMED], [INFOTRIEVE], [CSA]
- Waterer G W, Quasney M W, Cantor R M, Wunderink R G. Septic shock and respiratory failure in community-acquired pneumonia have different TNF polymorphism associations. Am J Respir Crit Care Med 2001; 163(7)1599–1604, [PUBMED], [INFOTRIEVE], [CSA]
- Kaijzel E L, Bayley J P, van Krugten M V, Smith L, van de Linde P, Bakker A M, Breedveld F C, Huizinga T W, Verweij C L. Allele-specific quantification of tumor necrosis factor alpha (TNF) transcription and the role of promoter polymorphisms in rheumatoid arthritis patients and healthy individuals. Genes Immun 2001; 2(3)135–144, [PUBMED], [INFOTRIEVE], [CSA]
- Oh B R, Sasaki M, Perinchery G, Ryu S B, Park Y I, Carroll P, Dahiya R. Frequent genotype changes at -308, and 488 regions of the tumor necrosis factor-alpha (TNF-alpha) gene in patients with prostate cancer. J Urol 2000; 163(5)1584–1587, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Mullighan C G, Fanning G C, Chapel H M, Welsh K I. TNF and lymphotoxin-alpha polymorphisms associated with common variable immunodeficiency: role in the pathogenesis of granulomatous disease. J Immunol 1997; 159(12)6236–6241, [PUBMED], [INFOTRIEVE], [CSA]
- Kubota T, McNamara D M, Wang J J, Trost M, McTiernan C F, Mann D L, Feldman A M. Effects of tumor necrosis factor gene polymorphisms on patients with congestive heart failure. VEST Investigators for TNF Genotype Analysis. Vesnarinone Survival Trial. Circulation 1998; 97(25)2499–2501, [PUBMED], [INFOTRIEVE], [CSA]
- Ozaki K, Ohnishi Y, Iida A, Sekine A, Yamada R, Tsunoda T, Sato H, Hori M, Nakamura Y, Tanaka T. Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction. Nat Genet 2002; 32(4)650–654, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Messer G, Spengler U, Jung M C, Honold G, Blomer K, Pape G R, Riethmuller G, Weiss E H. Polymorphic structure of the tumor necrosis factor (TNF) locus: an NcoI polymorphism in the first intron of the human TNF-beta gene correlates with a variant amino acid in position 26 and a reduced level of TNF-beta production. J Exp Med 1991; 173(1)209–219, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Knight J C, Keating B J, Kwiatkowski D P. Allele-specific repression of lymphotoxin-alpha by activated B cell factor-1. Nat Genet 2004; 36(4)394–399, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Makhatadze N J. Tumor necrosis factor locus: genetic organisation and biological implications. Hum Immunol 1998; 59(9)571–579, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Tomasdottir H, Hjartarson H, Ricksten A, Wasslavik C, Bengtsson A, Ricksten S E. Tumor necrosis factor gene polymorphism is associated with enhanced systemic inflammatory response and increased cardiopulmonary morbidity after cardiac surgery. Anesth Analg 2003; 97(4)944–949, table of contents[PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Trabetti E, Patuzzo C, Malerba G, Galavotti R, Martinati L C, Boner A L, Pignatti P F. Association of a lymphotoxin alpha gene polymorphism and atopy in Italian families. J Med Genet 1999; 36(4)323–325, [PUBMED], [INFOTRIEVE], [CSA]
- Patuzzo C, Gile L S, Zorzetto M, Trabetti E, Malerba G, Pignatti P F, Luisetti M. Tumor necrosis factor gene complex in COPD and disseminated bronchiectasis. Chest 2000; 117(5)1353–1358, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Lucas R, Juillard P, Decoster E, Redard M, Burger D, Donati Y, Giroud C, Monso-Hinard C, De Kesel T, Buurman W A, Moore M W, Dayer J M, Fiers W, Bluethmann H, Grau G E. Crucial role of tumor necrosis factor (TNF) receptor 2 and membrane-bound TNF in experimental cerebral malaria. Eur J Immunol 1997; 27(7)1719–1725, [PUBMED], [INFOTRIEVE], [CSA]
- Heller R A, Song K, Onasch M A, Fischer W H, Chang D, Ringold G M. Complementary DNA cloning of a receptor for tumor necrosis factor and demonstration of a shed form of the receptor. Proc Natl Acad Sci USA 1990; 87(16)6151–6155, [PUBMED], [INFOTRIEVE], [CSA]
- Pierik M, Vermeire S, Steen K V, Joossens S, Claessens G, Vlietinck R, Rutgeerts P. Tumour necrosis factor-alpha receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab. Aliment Pharmacol Ther 2004; 20(3)303–310, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Tolusso B, Sacco S, Gremese E, La Torre G, Tomietto P, Ferraccioli G F. Relationship between the tumor necrosis factor receptor II (TNF-RII) gene polymorphism and sTNF-RII plasma levels in healthy controls and in rheumatoid arthritis. Hum Immunol 2004; 65(12)1420–1426, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Dieude P, Petit E, Cailleau-Moindrault S, Osorio J, Pierlot C, Martinez M, Faure S, Alibert O, Lasbleiz S, De Toma C, Bardin T, Prum B, Cornelis F. Association between tumor necrosis factor receptor II and familial, but not sporadic, rheumatoid arthritis: evidence for genetic heterogeneity. Arthritis Rheum 2002; 46(8)2039–2044, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Morita C, Horiuchi T, Tsukamoto H, Hatta N, Kikuchi Y, Arinobu Y, Otsuka T, Sawabe T, Harashima S, Nagasawa K, Niho Y. Association of tumor necrosis factor receptor type II polymorphism 196R with Systemic lupus erythematosus in the Japanese: molecular and functional analysis. Arthritis Rheum 2001; 44(12)2819–2827, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Fabris M, Tolusso B, Di Poi E, Assaloni R, Sinigaglia L, Ferraccioli G. Tumor necrosis factor-alpha receptor II polymorphism in patients from southern Europe with mild-moderate and severe rheumatoid arthritis. J Rheumatol 2002; 29(9)1847–1850, [PUBMED], [INFOTRIEVE], [CSA]
- Fey G H, Gauldie J. The acute phase response of the liver in inflammation. Prog Liver Dis 1990; 9: 89–116, [PUBMED], [INFOTRIEVE], [CSA]
- Van Snick J. Interleukin-6: an overview. Annu Rev Immunol 1990; 8: 253–278, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Bucchioni E, Kharitonov S A, Allegra L, Barnes P J. High levels of interleukin-6 in the exhaled breath condensate of patients with COPD. Respir Med 2003; 97(12)1299–1302, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Song W, Zhao J, Li Z. Interleukin-6 in bronchoalveolar lavage fluid from patients with COPD. Chin Med J(Engl) 2001; 114(11)1140–1142, [CSA]
- Aldonyte R, Jansson L, Piitulainen E, Janciauskiene S. Circulating monocytes from healthy individuals and COPD patients. Respir Res 2003; 4(1)11, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Debigare R, Marquis K, Cote C H, Tremblay R R, Michaud A, Le Blanc P, Maltais F. Catabolic/anabolic balance and muscle wasting in patients with COPD. Chest 2003; 124(1)83–89, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Ridker P M, Rifai N, Stampfer M J, Hennekens C H. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101(15)1767–1772, [PUBMED], [INFOTRIEVE], [CSA]
- Lindmark E, Diderholm E, Wallentin L, Siegbahn A. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. JAMA 2001; 286(17)2107–2113, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Terry C F, Loukaci V, Green F R. Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J Biol Chem 2000; 275(24)18138–18144, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin J S, Humphries S, Woo P. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998; 102(7)1369–1376, [PUBMED], [INFOTRIEVE], [CSA]
- Endler G, Marsik C, Joukhadar C, Marculescu R, Mayr F, Mannhalter C, Wagner O F, Jilma B. The interleukin-6 G(-174)C promoter polymorphism does not determine plasma interleukin-6 concentrations in experimental endotoxemia in humans. Clin Chem 2004; 50(1)195–200, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Kubaszek A, Pihlajamaki J, Punnonen K, Karhapaa P, Vauhkonen I, Laakso M. The C-174G promoter polymorphism of the IL-6 gene affects energy expenditure and insulin sensitivity. Diabetes 2003; 52(2)558–561, [PUBMED], [INFOTRIEVE], [CSA]
- Vickers M A, Green F R, Terry C, Mayosi B M, Julier C, Lathrop M, Ratcliffe P J, Watkins H C, Keavney B. Genotype at a promoter polymorphism of the interleukin-6 gene is associated with baseline levels of plasma C-reactive protein. Cardiovasc Res 2002; 53(4)1029–1034, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Rivera-Chavez F A, Peters-Hybki D L, Barber R C, O'Keefe G E. Interleukin-6 promoter haplotypes and interleukin-6 cytokine responses. Shock 2003; 20(3)218–223, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Muller-Steinhardt M, Fricke L, Muller B, Ebel B, Kirchner H, Hartel C. Cooperative influence of the interleukin-6 promoter polymorphisms -597, -572 and -174 on long-term kidney allograft survival. Am J Transplant 2004; 4(3)402–406, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]